Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80).
Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80).
复制标题
针对侵袭性恶性淋巴瘤的强化序贯联合化疗（方案 LNH-80）。
DOI：
10.1200/jco.1986.4.2.147
复制
发表时间：
1986
期刊：
影响因子：
--
通讯作者：
J. Magaud
中科院分区：
文献类型：
--
作者：
Bertrand Coiffier;P. Bryon;Françoise Berger;E. Archimbaud;M. Ffrench;Extra Jm;Denis Guyotat;D. Fiére;O. Gentilhomme;J. Magaud
采用LNH-80方案，对97例侵袭性恶性淋巴瘤（ML）患者进行了强化序贯化疗。有42例中度ML患者，53例高度ML患者和2例真正的组织细胞ML患者。大多数患者处于晚期：21例III期和61例IV期。LNH-80方案时间表包括三个阶段：（1）诱导三个疗程的强化CHOP-Bleo（环磷酰胺、阿霉素、长春地辛、甲基强的松龙和博莱霉素）;（2）阿糖胞苷巩固治疗，随后是大剂量甲氨蝶呤和亚叶酸补救治疗，然后是门冬酰胺酶;和（3）最终强化，用两个疗程的CVAP-Bleo（环磷酰胺、替尼泊苷、阿糖胞苷、甲泼尼龙和博莱霉素）。CNS预防包括在每个诱导期注射一次甲氨蝶呤和巩固期药物。在初始CNS定位的病例中，增加了颅部放射治疗。84例患者（87%）达到完全缓解（CR），其中18例（21%）复发，通常在治疗期间或完成化疗后6个月内复发。63例患者存活，总体中位随访时间为24个月。中位生存时间和中位无病生存期尚未达到，生存曲线似乎已稳定在60%以上。中度ML（CR 90%，复发18%）和高度ML（CR 84%，复发24%）之间无统计学差异。这种治疗的毒性主要发生在诱导阶段：几乎所有患者都有短期中性粒细胞减少，57例患者低于0.500 g/L，25例患者记录感染。总体治疗相关死亡率为6%，其中4例患者在诱导期死亡。
Ninety-seven patients with aggressive malignant lymphoma (ML) were treated with an intensive and sequential chemotherapy (protocol LNH-80). There were 42 patients with intermediate grade ML, 53 patients with high-grade ML, and two patients with true histiocytic ML. Most of the patients were in advanced stage: 21 stage III and 61 stage IV. The LNH-80 protocol schedule comprised three phases: (1) induction with three courses of an intensified CHOP-Bleo (cyclophosphamide, doxorubicin, vindesine, methylprednisolone, and bleomycin); (2) consolidation with cytarabine, followed by high-dose methotrexate and folinic acid rescue, then asparaginase; and (3) final intensification with two courses of CVAP-Bleo (cyclophosphamide, teniposide, cytarabine, methylprednisolone, and bleomycin). CNS prophylaxis included one injection of methotrexate during each induction course and the drugs of the consolidation phase. In cases of initial CNS localization, cranial radiotherapy was added. Eighty-four patients (87%) went into complete remission (CR), 18 (21%) of whom relapsed, usually during the phase of treatment or within 6 months of completing chemotherapy. Sixty-three patients are alive with an overall median follow-up of 24 months. The median survival time and the median disease-free survival have not been reached, and the survival curve seems to have plateaued at above 60%. There was no statistical difference between intermediate-grade ML (CR 90%, relapse 18%) and high-grade ML (CR 84%, relapse 24%). The toxicity of this treatment is mainly encountered during the induction phase: almost all patients had short-term neutropenia, less than 0.500 g/L in 57, with a documented infection in 25. Overall treatment-related mortality was 6%, with four patients dying during the induction phase.
一项随机研究的后续行动，比较了晚期弥漫性组织细胞淋巴瘤的两种化疗方法。
DOI：
10.1200/jco.1984.2.9.986
发表时间：
1984
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Todd,M;Cadman,E;Spiro,P;Bertino,J;Farber,L;Waldron,J;Fischer,D
通讯作者：
Fischer,D